AMRZ Stock Analysis: Amrize | NYSE
Building Materials | NYSE, USA | Market Cap: 29.897m USD | 12M Return: -1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 148M
Qual. Beats: 0
Rev. Trend: 94.4%
Warnings
Tailwinds
No distinct edge detected
Seasonality 1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amrize AG is a Swiss-domiciled building solutions provider serving infrastructure, commercial, and residential construction markets across North America. The company operates through two segments: Building Materials, which supplies cement, aggregates, ready-mix concrete, asphalt, and other construction materials; and Building Envelope, which offers roofing and wall systems such as single-ply membranes, insulation, shingles, sheathing, waterproofing, protective coatings, adhesives, tapes, and sealants. Amrize was spun out as the North American business of global cement major Holcim and completed its NYSE listing (AMRZ) in June 2025.
The companys business model spans both upstream construction inputs (cement and aggregates) and downstream building components (roofing and wall systems), giving it a vertically integrated position across the North American construction value chain. Its GICS classification within the Construction Materials sub-industry places it among producers of commodity-heavy inputs whose demand tends to track infrastructure spending, housing starts, and non-residential construction cycles.
- US infrastructure spending boosts cement and aggregates demand
- Housing starts decline pressures North American construction volumes
- Cement price increases offset energy and labor cost inflation
| Net Income: 1.16b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.63 > 1.0 |
| NWC/Revenue: 10.33% < 20% (prev 11.08%; Δ -0.75% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.17b > Net Income 1.16b |
| Net Debt (6.62b) to EBITDA (2.77b): 2.39 < 3 |
| Current Ratio: 1.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (553.2m) vs 12m ago 0.09% < -2% |
| Gross Margin: 25.38% > 18% (prev 25.99%; Δ -0.61% > 0.5%) |
| Asset Turnover: 51.15% > 50% (prev 52.09%; Δ -0.94% > 0%) |
| Interest Coverage Ratio: 5.07 > 6 (EBIT TTM 1.85b / Interest Expense TTM 365.0m) |
| A: 0.05 (Total Current Assets 4.28b - Total Current Liabilities 3.05b) / Total Assets 24.3b |
| B: 0.03 (Retained Earnings 785.0m / Total Assets 24.3b) |
| C: 0.08 (EBIT TTM 1.85b / Avg Total Assets 23.3b) |
| D: 1.17 (Book Value of Equity 13.1b / Total Liabilities 11.2b) |
| Altman-Z'' = 2.20 = BBB |
| DSRI: 0.95 (Receivables 1.36b/1.40b, Revenue 11.9b/11.6b) |
| GMI: 1.02 (GM 25.99% / 25.38%) |
| AQI: 0.93 (AQ_t 0.45 / AQ_t-1 0.49) |
| SGI: 1.03 (Revenue 11.9b / 11.6b) |
| TATA: -0.04 (NI 1.16b - CFO 2.17b) / TA 24.3b) |
| Beneish M = -3.08 (Cap -4..+1) = AA |
As of July 10, 2026, the stock is trading at USD 50.28 with a total of 2,814,719 shares traded. Over the past week, the price has changed by -4.65%, over one month by -4.57%, over three months by -11.52% and over the past year by -1.00%.
Current recommended Stop Loss: 47.60 (which is 5.3% or 1.4 ATR below the current price).
Amrize has no consensus analysts rating.
P/E Trailing = 25.8421
P/E Forward = 18.7617
P/S = 2.5098
P/B = 2.2676
P/EG = 1.446
Revenue TTM = 11.9b USD
EBIT TTM = 1.85b USD
EBITDA TTM = 2.77b USD
Long Term Debt = 4.94b USD (from longTermDebt, last quarter)
Short Term Debt = 1.24b USD (from shortTermDebt, last quarter)
Debt = 7.72b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.05b
Net Debt = 6.62b USD (calculated: Debt 7.72b - CCE 1.10b)
Enterprise Value = 36.5b USD (29.9b + Debt 7.72b - CCE 1.10b)
Interest Coverage Ratio = 5.07 (Ebit TTM 1.85b / Interest Expense TTM 365.0m)
EV/FCF = 27.69x (Enterprise Value 36.5b / FCF TTM 1.32b)
FCF Yield = 3.61% (FCF TTM 1.32b / Enterprise Value 36.5b)
FCF Margin = 11.07% (FCF TTM 1.32b / Revenue TTM 11.9b)
Net Margin = 9.70% (Net Income TTM 1.16b / Revenue TTM 11.9b)
Gross Margin = 25.38% ((Revenue TTM 11.9b - Cost of Revenue TTM 8.89b) / Revenue TTM)
Gross Margin QoQ = 9.69% (prev 26.77%)
Tobins Q-Ratio = 1.50 (Enterprise Value 36.5b / Total Assets 24.3b)
Interest Expense / Debt = 4.73% (Interest Expense 365.0m / Debt 7.72b)
Taxrate = 23.06% (345.0m / 1.50b)
NOPAT = 1.42b (EBIT 1.85b * (1 - 23.06%))
Current Ratio = 1.40 (Total Current Assets 4.28b / Total Current Liabilities 3.05b)
Debt / Equity = 0.59 (Debt 7.72b / totalStockholderEquity, last quarter 13.1b)
Debt / EBITDA = 2.39 (Net Debt 6.62b / EBITDA 2.77b)
Debt / FCF = 5.02 (Net Debt 6.62b / FCF TTM 1.32b)
Total Stockholder Equity = 12.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.96% (Net Income 1.16b / Total Assets 24.3b)
RoE = 8.95% (Net Income TTM 1.16b / Total Stockholder Equity 12.9b)
RoCE = 10.36% (EBIT 1.85b / Capital Employed (Equity 12.9b + L.T.Debt 4.94b))
RoIC = 6.51% (NOPAT 1.42b / Invested Capital 21.9b)
WACC = 8.98% (E(29.9b)/V(37.6b) * Re(10.36%) + D(7.72b)/V(37.6b) * Rd(4.73%) * (1-Tc(0.23)))
Discount Rate = 10.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 58.04 | Cagr: 0.04%
[DCF] Terminal Value 72.90% ; FCFF base≈1.33b ; Y1≈1.31b ; Y5≈1.33b
[DCF] Fair Price = 22.01 (EV 18.8b - Net Debt 6.62b = Equity 12.2b / Shares 553.5m; r=8.98% [WACC]; 5y FCF grow -2.44% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.36 | # QB: 0
Revenue Correlation: 94.38 | Revenue CAGR: 0.59% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.01 | Chg30d=-0.31% | Revisions=+25% | Analysts=7
EPS next Quarter (2026-09-30): EPS=1.17 | Chg30d=-0.03% | Revisions=-25% | Analysts=7
EPS current Year (2026-12-31): EPS=2.69 | Chg30d=-0.20% | Revisions=+0% | GrowthEPS=+25.6% | GrowthRev=+5.2%
EPS next Year (2027-12-31): EPS=3.12 | Chg30d=-0.24% | Revisions=-12% | GrowthEPS=+16.1% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: -7% (up=5, down=6)